Biocon Biologics Joins Hands with IDF in its Mission to Promote
Annual Reports Archive
Biocon Limited: Research Report
Annual Reports
VIDEO
BIOCON SHARE ANALYSIS STOCK SHORT TERM TARGET
Introduction to Bioreactor Scale-Up & Development at Regeneron by Michelle LaFond
Kiran Mazumdar Shaw On Tracking Biocon's Stock Performance
NGS Revolutionizing Cancer Research: Advantages & Applications #NGS #cancerresearch #biotechnology
Biocon Share Latest News
22 August 🔴 Biocon Share
COMMENTS
Biocon Ltd. Brokerage/Research Reports, analyst Research ...
Biocon Ltd. share price target. View 13 reports from 6 analysts offering long term price targets for Biocon Ltd.. Biocon Ltd. has an average target of 260.33. The consensus estimate represents a downside of -3.92% from the last price of 270.9500. Reco - This broker has downgraded this stock from it's previous report.
PDF Biocon ESG Summary Report 2021
ESG SUMMARY REPORT 2021 UNCONDITIONAL EQUITY Biocon Limited At Biocon, we are driven by a humanitarian purpose to make healthcare affordable and accessible to even the poorest of patients. This philosophy resonates with our Environmental, Social and Governance (ESG) practices, which rest on a bedrock of purpose, ethics and equity. Unconditional ...
FY: From April 1 - March 31. Know more. about us. >> Biocon Malaysia. >> Bicara. >> Syngene. Access our latest Biocon Annual report 2023- Relentless Pursuit. Differentiated Growth.
PDF Transform Action
The FY22 ESG Report includes disclosures on the non-financial performance of Biocon Limited and Biocon Biologics Limited, excluding Syngene International, for the period 1st April 2021 to 31st March 2022. The reporting boundary further extends to include discussions on sustainability factors that impact the company's ability to
Biocon Ltd 9021
Biocon's share price has grown by ~1.3x over the past three years (from ~₹ 237 in July 2019 to ~₹ 309 levels in July 2022). We maintain HOLD due to 1) growing margins sensitivity, 2) Viatris deal and subsequent execution risks and 3) impending price erosion risks, regulatory issues and increasing competitive landscape.
Biocon Ltd (BIOCON)
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal ...
Stock Research Report for Biocon Ltd
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs ...
PDF Growth Through Integrated Research
ANNUAL REPORT 2012 Growth Through Integrated Research Growth Through Integrated Research ANNUAL REPORT 2012 www.biocon.com Biocon Limited 20th KM Hosur Road Electronic City Bangalore 560 100 India T 91 80 2808 2808 F 91 80 2852 3423 21201379_Biocon AR 2012_Cov New.indd 1 18/06/12 2:28 PM
Biocon Q3 Results Review
Motilal Oswal Report. Biocon Ltd.'s Q3 FY24 earnings came in below our estimates, due to increased operational costs. A moderation in active pharma ingredient (generics) and discovery services (Syngene) and the transition to full integration in the biosimilar segment affected the Q3 performance. We cut our earnings estimates for FY24/FY25 ...
Biocon Ltd (BIOCON) Stock Price & News
Get the latest Biocon Ltd (BIOCON) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Biocon
Biocon Ltd. has delivered 22%/25% revenue/Ebitda compound annual growth rate over FY18-23, led by robust traction in biosimilars and research services. However, earnings CAGR have been lower at 15% over FY18-23 due to increased financial leverage and depreciation.
Annual Report 2020
The report aims to provide an insight into our financial and non-financial performance, addressing the growing interest and expectations of our global stakeholders across Environmental, Social and Governance (ESG) domains. INTEGRATED ANNUAL REPORT. 2022-23. BRSR, GRI & ESG DATA BOOK. 2022-23. Access our latest Biocon Annual report 2020 - The ...
Biocon
We recently met with Biocon's management to understand its business outlook in greater detail. key takeaways After two years (FY20/FY21) of earnings decline, Biocon is well-positioned to revive earnings growth meaningfully. to steady traction in already launched Biosimilars, Biocon has insulin Glargine (Semglee) contracts starting Q4FY22.
PDF THE
Biocon Foundation Biocon Academy FINANCIAL REPORTS 87 Board's Report 127 Management Discussion and Analysis 148 Corporate Governance Report 169 Business Responsibility Report 181 Standalone Financial Statements 243 Consolidated Financial Statements Scan the QR code to download the Annual Report on your mobile device. Visit us at: www.biocon.com
PDF Biocon Ltd (BIOCON) Beat on estimates, e
About the stock: Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris' biosimilars assets for US$3.335 billion. Biocon Biologics entered into a strategic
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, "Biocon's consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 Crore, driven by a strong performance across all business segments. Biosimilars grew by 28% to Rs 981 Crore, Research Services was up 10% at Rs 641 Crore and Generics delivered a 7% growth ...
Biocon Ltd. Share Price Today: CLOSE 264.15, HIGH 266.75, LOW: 259.2. Get latest balance sheet, annual reports, quarterly results, and price chart.
Biocon Reports
Biocon Reports - Industry Research. Reports Featuring Biocon. North America Human Insulin Drugs Market. The North America Human Insulin Drugs Market size is estimated at USD 11.58 billion in 2024, and is expected to reach USD 14.03 billion by 2029, growing at a CAGR of 3.91% during the forecast period (2024-2029).
PDF 22 January 2021 Biocon
22 January 2021 3QFY21. Results Update| Sector: Healthcare Biocon. Tushar Manudhane - Research Analyst ([email protected]) . Bharat Hegde, CFA - Research Analyst ([email protected]) . Investors are advised to refer through important disclosures made at the last page of the Research Report.
Generic Anti-Obesity Drugs Get Boost With UK Approval for Biocon
Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that's expected to touch $100 billion by 2030. The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide ...
Biocon Biologics Continues to Expand Global Footprint, Completes
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to ...
New pancreatic cancer test shows promise in early data at AACR
Early data on a new blood test, which looks for bits of RNA discharged by tumors, suggests it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%.
STAT+: Pharmalittle: We're reading about Biocon eyeing ...
Five months after setting out a controversial new vision, Sanofi has informed employees some will lose their jobs as a result, Fierce Biotech reports. About 230 words into what appeared to be an ...
Research & Development
At Biocon, Research & Development in conjugation with innovation and collaboration, is set to redefine the success path. CONTACT +91 80 2808 2808 . [email protected] . About Us. Overview; Who we are ... Report adverse event/ side effects and/or product complaints for Biocon products.
IMAGES
VIDEO
COMMENTS
Biocon Ltd. share price target. View 13 reports from 6 analysts offering long term price targets for Biocon Ltd.. Biocon Ltd. has an average target of 260.33. The consensus estimate represents a downside of -3.92% from the last price of 270.9500. Reco - This broker has downgraded this stock from it's previous report.
ESG SUMMARY REPORT 2021 UNCONDITIONAL EQUITY Biocon Limited At Biocon, we are driven by a humanitarian purpose to make healthcare affordable and accessible to even the poorest of patients. This philosophy resonates with our Environmental, Social and Governance (ESG) practices, which rest on a bedrock of purpose, ethics and equity. Unconditional ...
FY: From April 1 - March 31. Know more. about us. >> Biocon Malaysia. >> Bicara. >> Syngene. Access our latest Biocon Annual report 2023- Relentless Pursuit. Differentiated Growth.
The FY22 ESG Report includes disclosures on the non-financial performance of Biocon Limited and Biocon Biologics Limited, excluding Syngene International, for the period 1st April 2021 to 31st March 2022. The reporting boundary further extends to include discussions on sustainability factors that impact the company's ability to
Biocon's share price has grown by ~1.3x over the past three years (from ~₹ 237 in July 2019 to ~₹ 309 levels in July 2022). We maintain HOLD due to 1) growing margins sensitivity, 2) Viatris deal and subsequent execution risks and 3) impending price erosion risks, regulatory issues and increasing competitive landscape.
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal ...
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs ...
ANNUAL REPORT 2012 Growth Through Integrated Research Growth Through Integrated Research ANNUAL REPORT 2012 www.biocon.com Biocon Limited 20th KM Hosur Road Electronic City Bangalore 560 100 India T 91 80 2808 2808 F 91 80 2852 3423 21201379_Biocon AR 2012_Cov New.indd 1 18/06/12 2:28 PM
Motilal Oswal Report. Biocon Ltd.'s Q3 FY24 earnings came in below our estimates, due to increased operational costs. A moderation in active pharma ingredient (generics) and discovery services (Syngene) and the transition to full integration in the biosimilar segment affected the Q3 performance. We cut our earnings estimates for FY24/FY25 ...
Get the latest Biocon Ltd (BIOCON) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Biocon Ltd. has delivered 22%/25% revenue/Ebitda compound annual growth rate over FY18-23, led by robust traction in biosimilars and research services. However, earnings CAGR have been lower at 15% over FY18-23 due to increased financial leverage and depreciation.
The report aims to provide an insight into our financial and non-financial performance, addressing the growing interest and expectations of our global stakeholders across Environmental, Social and Governance (ESG) domains. INTEGRATED ANNUAL REPORT. 2022-23. BRSR, GRI & ESG DATA BOOK. 2022-23. Access our latest Biocon Annual report 2020 - The ...
We recently met with Biocon's management to understand its business outlook in greater detail. key takeaways After two years (FY20/FY21) of earnings decline, Biocon is well-positioned to revive earnings growth meaningfully. to steady traction in already launched Biosimilars, Biocon has insulin Glargine (Semglee) contracts starting Q4FY22.
Biocon Foundation Biocon Academy FINANCIAL REPORTS 87 Board's Report 127 Management Discussion and Analysis 148 Corporate Governance Report 169 Business Responsibility Report 181 Standalone Financial Statements 243 Consolidated Financial Statements Scan the QR code to download the Annual Report on your mobile device. Visit us at: www.biocon.com
About the stock: Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris' biosimilars assets for US$3.335 billion. Biocon Biologics entered into a strategic
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, "Biocon's consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 Crore, driven by a strong performance across all business segments. Biosimilars grew by 28% to Rs 981 Crore, Research Services was up 10% at Rs 641 Crore and Generics delivered a 7% growth ...
Biocon Ltd. Share Price Today: CLOSE 264.15, HIGH 266.75, LOW: 259.2. Get latest balance sheet, annual reports, quarterly results, and price chart.
Biocon Reports - Industry Research. Reports Featuring Biocon. North America Human Insulin Drugs Market. The North America Human Insulin Drugs Market size is estimated at USD 11.58 billion in 2024, and is expected to reach USD 14.03 billion by 2029, growing at a CAGR of 3.91% during the forecast period (2024-2029).
22 January 2021 3QFY21. Results Update| Sector: Healthcare Biocon. Tushar Manudhane - Research Analyst ([email protected]) . Bharat Hegde, CFA - Research Analyst ([email protected]) . Investors are advised to refer through important disclosures made at the last page of the Research Report.
Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that's expected to touch $100 billion by 2030. The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide ...
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to ...
Early data on a new blood test, which looks for bits of RNA discharged by tumors, suggests it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%.
Five months after setting out a controversial new vision, Sanofi has informed employees some will lose their jobs as a result, Fierce Biotech reports. About 230 words into what appeared to be an ...
At Biocon, Research & Development in conjugation with innovation and collaboration, is set to redefine the success path. CONTACT +91 80 2808 2808 . [email protected] . About Us. Overview; Who we are ... Report adverse event/ side effects and/or product complaints for Biocon products.